Cargando…

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications

PURPOSE: Management of recurrent prostate cancer necessitates timely diagnosis and accurate localization of the sites of recurrent disease. The purpose of this study was to assess predictors of histologic outcomes after 11C-choline positron emission tomography/computed tomography (CholPET) to increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Welch, Brian T., Packard, Ann T., Atwell, Thomas D., Johnson, Geoffrey B., Lowe, Val J., Karnes, Robert Jeffrey, Mynderse, Lance A., Gunderson, Tina M., Park, Sean S., Stish, Bradley J., Evans, Jaden D., Kwon, Eugene D., Davis, Brian J., Nathan, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349661/
https://www.ncbi.nlm.nih.gov/pubmed/30706014
http://dx.doi.org/10.1016/j.adro.2018.08.022
_version_ 1783390292996521984
author Welch, Brian T.
Packard, Ann T.
Atwell, Thomas D.
Johnson, Geoffrey B.
Lowe, Val J.
Karnes, Robert Jeffrey
Mynderse, Lance A.
Gunderson, Tina M.
Park, Sean S.
Stish, Bradley J.
Evans, Jaden D.
Kwon, Eugene D.
Davis, Brian J.
Nathan, Mark A.
author_facet Welch, Brian T.
Packard, Ann T.
Atwell, Thomas D.
Johnson, Geoffrey B.
Lowe, Val J.
Karnes, Robert Jeffrey
Mynderse, Lance A.
Gunderson, Tina M.
Park, Sean S.
Stish, Bradley J.
Evans, Jaden D.
Kwon, Eugene D.
Davis, Brian J.
Nathan, Mark A.
author_sort Welch, Brian T.
collection PubMed
description PURPOSE: Management of recurrent prostate cancer necessitates timely diagnosis and accurate localization of the sites of recurrent disease. The purpose of this study was to assess predictors of histologic outcomes after 11C-choline positron emission tomography/computed tomography (CholPET) to increase the positive predictive value and specificity of CholPET in identifying imaging predictors of malignant and benign nodal disease to better inform clinical decision making regarding local therapy planning. MATERIALS AND METHODS: Retrospective review of patients undergoing CholPET followed by percutaneous core needle biopsy between January 1, 2010 and January 1, 2016. A total of 153 patients were identified who underwent 166 biopsy procedures. Patient, CholPET, procedural, and pathologic characteristics were recorded. RESULTS: A total of 157 biopsies were technically successful, and 110 (70.1%; 95% confidence interval, 62.2-77.1) yielded histologic results abnormal for metastatic prostate cancer. Lesion location, lesion maximum standardized uptake value (SUVmax), SUV ratio (calculated as the ratio of SUVmax to SUV mean in the right atrium), prostate-specific antigen, lesion short axis length, total Gleason score, and castration resistance were all associated with abnormal biopsy results (P values <.001, <.001, <.001, .02, .02, .02, and .015, respectively). External iliac, common iliac, and inguinal sites were associated with much lower rates of histologic positivity (mean [95% confidence interval], 51.2% [35.1-67.1], 46.2% [19.2-74.9], and 33.3% [7.5-70.1]), respectively. CONCLUSIONS: In a cohort of patients in whom core needle biopsy was performed after CholPET, characteristics of choline localization including node location, SUVmax, lesion–to–blood pool SUV ratio, prostate-specific antigen, total Gleason score, and castration resistance were significantly associated with abnormal biopsy results for metastatic disease on CholPET. Relatively high false positive rates were found in common iliac, external iliac, and inguinal lymph node locations. Histologic confirmation of these sites should be strongly considered in the appropriate clinical scenario before designing additional local therapy plans.
format Online
Article
Text
id pubmed-6349661
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63496612019-01-31 Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications Welch, Brian T. Packard, Ann T. Atwell, Thomas D. Johnson, Geoffrey B. Lowe, Val J. Karnes, Robert Jeffrey Mynderse, Lance A. Gunderson, Tina M. Park, Sean S. Stish, Bradley J. Evans, Jaden D. Kwon, Eugene D. Davis, Brian J. Nathan, Mark A. Adv Radiat Oncol Genitourinary Cancer PURPOSE: Management of recurrent prostate cancer necessitates timely diagnosis and accurate localization of the sites of recurrent disease. The purpose of this study was to assess predictors of histologic outcomes after 11C-choline positron emission tomography/computed tomography (CholPET) to increase the positive predictive value and specificity of CholPET in identifying imaging predictors of malignant and benign nodal disease to better inform clinical decision making regarding local therapy planning. MATERIALS AND METHODS: Retrospective review of patients undergoing CholPET followed by percutaneous core needle biopsy between January 1, 2010 and January 1, 2016. A total of 153 patients were identified who underwent 166 biopsy procedures. Patient, CholPET, procedural, and pathologic characteristics were recorded. RESULTS: A total of 157 biopsies were technically successful, and 110 (70.1%; 95% confidence interval, 62.2-77.1) yielded histologic results abnormal for metastatic prostate cancer. Lesion location, lesion maximum standardized uptake value (SUVmax), SUV ratio (calculated as the ratio of SUVmax to SUV mean in the right atrium), prostate-specific antigen, lesion short axis length, total Gleason score, and castration resistance were all associated with abnormal biopsy results (P values <.001, <.001, <.001, .02, .02, .02, and .015, respectively). External iliac, common iliac, and inguinal sites were associated with much lower rates of histologic positivity (mean [95% confidence interval], 51.2% [35.1-67.1], 46.2% [19.2-74.9], and 33.3% [7.5-70.1]), respectively. CONCLUSIONS: In a cohort of patients in whom core needle biopsy was performed after CholPET, characteristics of choline localization including node location, SUVmax, lesion–to–blood pool SUV ratio, prostate-specific antigen, total Gleason score, and castration resistance were significantly associated with abnormal biopsy results for metastatic disease on CholPET. Relatively high false positive rates were found in common iliac, external iliac, and inguinal lymph node locations. Histologic confirmation of these sites should be strongly considered in the appropriate clinical scenario before designing additional local therapy plans. Elsevier 2018-09-05 /pmc/articles/PMC6349661/ /pubmed/30706014 http://dx.doi.org/10.1016/j.adro.2018.08.022 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Genitourinary Cancer
Welch, Brian T.
Packard, Ann T.
Atwell, Thomas D.
Johnson, Geoffrey B.
Lowe, Val J.
Karnes, Robert Jeffrey
Mynderse, Lance A.
Gunderson, Tina M.
Park, Sean S.
Stish, Bradley J.
Evans, Jaden D.
Kwon, Eugene D.
Davis, Brian J.
Nathan, Mark A.
Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title_full Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title_fullStr Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title_full_unstemmed Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title_short Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
title_sort percutaneous image-guided nodal biopsy after 11c-choline pet/ct for biochemically recurrent prostate cancer: imaging predictors of disease and clinical implications
topic Genitourinary Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349661/
https://www.ncbi.nlm.nih.gov/pubmed/30706014
http://dx.doi.org/10.1016/j.adro.2018.08.022
work_keys_str_mv AT welchbriant percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT packardannt percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT atwellthomasd percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT johnsongeoffreyb percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT lowevalj percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT karnesrobertjeffrey percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT mynderselancea percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT gundersontinam percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT parkseans percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT stishbradleyj percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT evansjadend percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT kwoneugened percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT davisbrianj percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications
AT nathanmarka percutaneousimageguidednodalbiopsyafter11ccholinepetctforbiochemicallyrecurrentprostatecancerimagingpredictorsofdiseaseandclinicalimplications